KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q1 2025 value amounting to $117.4 million.

  • Rigel Pharmaceuticals' Total Non-Current Liabilities fell 66.32% to $117.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $117.4 million, marking a year-over-year decrease of 66.32%. This contributed to the annual value of $120.7 million for FY2024, which is 1395.52% up from last year.
  • Rigel Pharmaceuticals' Total Non-Current Liabilities amounted to $117.4 million in Q1 2025, which was down 66.32% from $120.7 million recorded in Q4 2024.
  • In the past 5 years, Rigel Pharmaceuticals' Total Non-Current Liabilities registered a high of $120.7 million during Q4 2024, and its lowest value of $80.2 million during Q1 2021.
  • In the last 5 years, Rigel Pharmaceuticals' Total Non-Current Liabilities had a median value of $105.6 million in 2022 and averaged $100.7 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Total Non-Current Liabilities surged by 3390.69% in 2021 and then tumbled by 66.32% in 2025.
  • Rigel Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $84.2 million in 2021, then rose by 25.41% to $105.6 million in 2022, then grew by 0.28% to $105.9 million in 2023, then grew by 13.96% to $120.7 million in 2024, then fell by 2.72% to $117.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $117.4 million for Q1 2025, versus $120.7 million for Q4 2024 and $114.1 million for Q3 2024.